Congestive Heart Failure (CHF) – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040
- Published Date : October 30, 2025
- Updated On : June 1, 2026
- Pages : 52
Congestive Heart Failure Global Epidemiology Insights and Disease Burden
Thelansis’s “Congestive Heart Failure Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Congestive Heart Failure Overview
Congestive heart failure (CHF) is a progressive syndrome where structural or functional cardiac defects impair ventricular filling or ejection. Driven by maladaptive neurohormonal hyperactivation and pathological remodeling, CHF is primarily classified by ejection fraction: reduced (HFrEF) or preserved (HFpEF). Patients present with exertional dyspnea, profound fatigue, orthopnea, and volume overload manifesting as pulmonary or peripheral edema. Diagnosis relies on elevated natriuretic peptides (BNP/NT-proBNP) and echocardiography to quantify function. The therapeutic paradigm has completely transformed, shifting away from slow, sequential treatment toward the rapid, concurrent initiation of the foundational “four pillars” of guideline-directed medical therapy for HFrEF: ARNIs (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Crucially, SGLT2 inhibitors are now firmly established as the primary cornerstone therapy for historically untreatable HFpEF. Furthermore, GLP-1 receptor agonists (semaglutide) have recently demonstrated profound functional benefits in obesity-related HFpEF phenotypes. Advanced disease management integrates sGC stimulators (vericiguat), intravenous iron, device therapy (CRT/ICDs), and ultimately mechanical circulatory support.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Congestive Heart Failure Global Epidemiology Insights and Disease Burden
Thelansis’s “Congestive Heart Failure Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Congestive Heart Failure Overview
Congestive heart failure (CHF) is a progressive syndrome where structural or functional cardiac defects impair ventricular filling or ejection. Driven by maladaptive neurohormonal hyperactivation and pathological remodeling, CHF is primarily classified by ejection fraction: reduced (HFrEF) or preserved (HFpEF). Patients present with exertional dyspnea, profound fatigue, orthopnea, and volume overload manifesting as pulmonary or peripheral edema. Diagnosis relies on elevated natriuretic peptides (BNP/NT-proBNP) and echocardiography to quantify function. The therapeutic paradigm has completely transformed, shifting away from slow, sequential treatment toward the rapid, concurrent initiation of the foundational “four pillars” of guideline-directed medical therapy for HFrEF: ARNIs (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Crucially, SGLT2 inhibitors are now firmly established as the primary cornerstone therapy for historically untreatable HFpEF. Furthermore, GLP-1 receptor agonists (semaglutide) have recently demonstrated profound functional benefits in obesity-related HFpEF phenotypes. Advanced disease management integrates sGC stimulators (vericiguat), intravenous iron, device therapy (CRT/ICDs), and ultimately mechanical circulatory support.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)